Publications by authors named "Peter D Feldman"

Claim this Profile
A
A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions.
Yoko Tanaka, Luis A Rohde, Ling Jin, Peter D Feldman, Himanshu P Upadhyaya

J Child Adolesc Psychopharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.
Haya Ascher-Svanum, William S Montgomery, David P McDonnell, Kristina A Coleman, Peter D Feldman

Int J Gen Med· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia.
Haya Ascher-Svanum, Alan Jm Brnabic, Anthony H Lawson, Bruce J Kinon, Virginia L Stauffer, Peter D Feldman

Neuropsychiatr Dis Treat· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
Virginia L Stauffer, Guochen Song, Bruce J Kinon, Haya Ascher-Svanum, Lei Chen, Peter D Feldman

Schizophr Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
Hong Liu-Seifert, Olawale O Osuntokun, Peter D Feldman

Compr Psychiatry· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
David P McDonnell, Ludmila A Kryzhanovskaya, Fangyi Zhao, Holland C Detke, Peter D Feldman

Hum Psychopharmacol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient perspectives on antipsychotic treatments and their association with clinical outcomes.
Hong Liu-Seifert, Olawale O Osuntokun, Jenna L Godfrey, Peter D Feldman

Patient Prefer Adherence· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Richard C Mohs, Thomas M Shiovitz, Pierre N Tariot, Anton P Porsteinsson, Kurt D Baker, Peter D Feldman

Am J Geriatr Psychiatry· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.
Jan K Buitelaar, Timothy E Wilens, Shuyu Zhang, Yu Ning, Peter D Feldman

J Child Psychol Psychiatry· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.
Paula T Trzepacz, David W Williams, Peter D Feldman, Rebecca E Wrishko, Jennifer W Witcher

Eur Neuropsychopharmacol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
Thomas J Spencer, F Randy Sallee, Donald L Gilbert, David W Dunn, James T McCracken, Peter D Feldman

J Atten Disord· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.
Thomas J Spencer, Christopher J Kratochvil, R Bart Sangal, Keith E Saylor, Charles E Bailey, Peter D Feldman

J Child Adolesc Psychopharmacol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Humberto Quintana, Edward A Cherlin, David A Duesenberg, Mark E Bangs, Janet L Ramsey, Peter D Feldman

Clin Ther· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.
Laurence L Greenhill, Jeffrey H Newcorn, Haitao Gao, Peter D Feldman

J Am Acad Child Adolesc Psychiatry· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
Joseph Biederman, Thomas J Spencer, Jeffrey H Newcorn, Haitao Gao, Denái R Milton, Peter D Feldman

Psychopharmacology (Berl)· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder.
Christopher J Kratochvil, Timothy E Wilens, Laurence L Greenhill, Haitao Gao, Kurt D Baker, Peter D Feldman

J Am Acad Child Adolesc Psychiatry· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Timothy E Wilens, Jeffrey H Newcorn, Christopher J Kratochvil, Haitao Gao, Christine K Thomason, Peter D Feldman

J Pediatr· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.
Kelvin L Chou, Susan Messing, David Oakes, Peter D Feldman, Alan Breier

Clin Neuropharmacol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Walter G Deberdt, Maurice W Dysken, Stephen A Rappaport, Peter D Feldman, Carrie A Young

Am J Geriatr Psychiatry· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine and tics in ADHD.
Peter D Feldman, Dustin D Ruff, Albert J Allen

J Am Acad Child Adolesc Psychiatry· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.
Mauricio Tohen, K N Roy Chengappa, Trisha Suppes, Robert W Baker, Carlos A Zarate, Peter D Feldman

Br J Psychiatry· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
Peter D Feldman, Linda K Hay, Walter Deberdt, John S Kennedy, David S Hutchins

J Am Med Dir Assoc· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.
Peter Paul De Deyn, Manuel Martín Carrasco, Walter Deberdt, Claude Jeandel, Donald P Hay, Peter D Feldman

Int J Geriatr Psychiatry· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
Istvan Bitter, Martin R K Dossenbach, Shlomo Brook, Peter D Feldman, Stephen Metcalfe

Prog Neuropsychopharmacol Biol Psychiatry· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Peter D Feldman, Christopher J Kaiser, John S Kennedy, Virginia K Sutton, Pierre V Tran

J Clin Psychiatry· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis